Rapid and validated UHPLC method for simultaneous determination of sofosbuvir, ledipasvir and paracetamol as commonly repurposed drugs for COVID-19 treatment: application in spiked human plasma

Rapid and validated UHPLC method for simultaneous determination of sofosbuvir, ledipasvir and paracetamol as commonly repurposed drugs for COVID-19 treatment: application in spiked human plasma

Abstract Background Sofosbuvir/ledipasvir (SOF/LDV), a combination of antiviral drugs, has been recently repurposed for COVID-19 management, according to Food and Drug Administration approval. Paracetamol (PAR) identified as a first-line antipyretic for COVID-19 symptoms' management. The use of...

Full description

Bibliographic Details
Main Authors: Sherif Gamal, Gehad G. Mohamed, Said A. Salih, Menna I. Ezzeldin, Asmaa A. Mandour
Format: Article
Language:English
Published: SpringerOpen 2023-10-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
UHPLC
Sofosbuvir
Ledipasvir
Paracetamol
COVID-19
Human plasma
Online Access:https://doi.org/10.1186/s43094-023-00548-3

Similar Items

Similar Items